Single-use bioreactors market set to reach $9.2 billion by 2032, driven by biopharmaceutical demand.

From GlobeNewswire: 2024-04-30 06:30:00

The Single-use Bioreactors Market is expected to reach a value of USD 9.2 billion by 2032, driven by the demand for biopharmaceuticals and the need for scalable manufacturing solutions. Terumo Blood and Cell Technologies’ Quantum Flex Cell Expansion System offers benefits like healthier cells for cell and gene therapy makers. Single-use bioreactors reduce contamination risk and streamline production processes, leading to increased adoption.

Gene therapy segment in the single-use bioreactors market will see significant growth due to the rising need to treat genetic disorders and cancer. Single-use bioreactors provide flexibility and scalability for producing viral vectors and gene therapy products, catering to the fast-paced nature of gene therapy practices. Modular designs also enable rapid development in this segment.

The contract manufacturing organization (CMO) segment is forecasted to witness strong expansion till 2032, as biopharmaceutical companies outsource manufacturing operations. Single-use bioreactors reduce setup time, lower operational costs, and enhance flexibility, allowing CMOs to optimize production processes. The disposable nature of single-use systems eliminates the need for extensive cleaning procedures, accelerating time-to-market for biopharmaceutical products.

The Asia Pacific single-use bioreactors market is expected to grow significantly by 2032, driven by the region’s growing biopharmaceutical sector and R&D investments. Flexible and rapid deployment solutions offered by single-use bioreactors are attracting regional firms. Regulatory support for advanced bioprocessing technologies and healthcare infrastructure development will further boost industry expansion in the region.



Read more at GlobeNewswire: Single-use Bioreactors Market to hit USD 9.2 Bn by 2032,